Interesting ImagesFDG PET/CT in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell LymphomaAngamuthu, Meivel MD∗; Kaur, Kanwaljeet MD†; Tripathi, Madhavi MD∗; Meena, Jagdish Prasad MD†; Seth, Rachna MD†; Kumar, Rakesh MD, PhD, FAMS∗Author Information From the ∗Division of Diagnostic Nuclear Medicine, Department of Nuclear Medicine †Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. Received for publication November 15, 2019; revision accepted March 15, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Rakesh Kumar, MD, PhD, FAMS, Division of Diagnostic Nuclear Medicine, Department of Nuclear Medicine, All India Institute of Medical Sciences New Delhi-110029, India. E-mail: email@example.com. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p 540-541 doi: 10.1097/RLU.0000000000003071 Buy Metrics Abstract Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin’s lymphoma, with rearrangements of the anaplastic lymphoma kinase gene in 60%–85% of systemic cases. We report an 11-year-old boy with ALCL in whom serial FDG PET/CT revealed partial response and complete metabolic response at interim and end of treatment, respectively. However, the patient relapsed within 2 weeks, confirmed by cytology. Because of the inherent aggressive nature of ALCL, possibility of an early relapse should always be kept in mind. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.